Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 2, 2025
Daily News
October 2, 2025
- AbbVie Aims for Neuroscience Leadership, CSO Says in Tokyo
October 2, 2025
- Think Tanks Urge Unique Value Framework for Regenerative Medicine in 2026 Reform
October 2, 2025
- Kyorin Bags Japan Rights to Hinge Bio’s SLE Med
October 2, 2025
- JCR Out-Licenses Fabry Drug to Oman’s Menagen for MENAT Region
October 2, 2025
- Specialist Urges More COVID Shots for Elderly amid “13th Wave”
October 2, 2025
- Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan
October 2, 2025
- Teijin, Australian CDMO Form Alliance for Cell and Gene Therapies in Asia-Pacific
October 2, 2025
- Fuji Pharma Seeks Dysmenorrhea Use for Nextstellis in Thailand
October 2, 2025
- Chugai’s PiaSky Now Available in Taiwan for PNH
October 2, 2025
- JETRO Launches Japan Entry Program for Regenerative Medicine Startups
October 2, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…